Max Chat
Calendrier des promotions BriaCell Therapeutics Corp.
Calendrier avancé
Graphique simple
À propos de l'entreprise BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Paramètres de base
IPO date
2021-02-24
ISIN
CA10778Y3023
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0 | 0 |
| P/BV | -67.75 | 0 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -28.55 | 0 |
| ROE | 153.14 | 10 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | 0 | 10 |
| Debt/Ratio | 0 | 10 |
| Debt/Equity | -3.19 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 0 | 0 |
| Rentabilité Ebitda, % | -440.84 | 0 |
| Rentabilité EPS, % | -114.93 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 3.12 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 3.49 $ | 0 $ | 0 $ | -10.6 % | 0 % | 0 % |
| common.calendar.number_days.30d | 3.07 $ | 3.12 $ | 3.53 $ | 1.63 % | 0 % | 0 % |
| common.calendar.number_days.90d | 4.35 $ | 2.92 $ | 6.03 $ | -28.28 % | 0 % | 0 % |
| common.calendar.number_days.180d | 3.73 $ | 0.378 $ | 6.87 $ | -16.35 % | 0 % | 0 % |
| common.calendar.number_days.1y | 0.795 $ | 0.378 $ | 18.6 $ | 292.45 % | 0 % | 0 % |
| common.calendar.number_days.3y | 6.96 $ | 0.378 $ | 18.6 $ | -55.17 % | 0 % | 0 % |
| common.calendar.number_days.5y | 7.92 $ | 0.378 $ | 18.6 $ | -60.63 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.0283 $ | 0.0283 $ | 19.76 $ | 11024.73 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 4.48 $ | 0.378 $ | 9.61 $ | -30.36 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Dr. William V. Williams M.D. | CEO, President & Director | 785.3k | 1955 (70 années) |
| Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. | CFO & Corporate Secretary | 304.46k | 1973 (52 année) |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer | 298.9k | 1969 (56 années) |
| Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer | 492.5k | 1962 (63 année) |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor & Member of Scientific Advisory Board | 241.14k | 1946 (79 années) |
Informations sur l'entreprise
Adresse: Canada, West Vancouver. BC VT X, Bellevue Centre - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://briacell.com
Site web: https://briacell.com
